Applications for San Francisco (Batch 12) extended AGAIN through September 30th, 2021!

Learn more about investing in Girihlet

Our team will get back to you soon to follow up on your inquiry.
Girihlet
T-cell sequencing to monitor health
Founded
2012
Employees*
1-10
Funding to Date*
$2.8M
Website
girihlet.com
Anitha Jayaprakash, PhD, CEO
We think measuring your immune system is a more complete window to your health because it’s highly dynamic, predictive, and retains memories of past events.
Your immune system is the first one to detect cancer cells

The complexity and growing prevalence of autoimmune disorders demands attention. Baked into our immune cells are records of the interplay between the genome, diet, and the environment.

Girihlet’s patented approach to sequencing T-cell receptors (TCR) unlocks these complex interactions by classifying TCRs into actionable biomarkers to diagnose and identify treatment avenues for autoimmune diseases.